Please assess the completion status of the following clinical trial:

Trial Title: PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 1 diabetes confirmed by C peptide measurements.~* Male and Female subjects of all races will be included in this study.~* Subjects age must be between 13 to 50 years~* Duration of the disease (from time of diagnosis of diabetes) must be between 5 to 28 years.~* Subjects must be normotensive defined as a systolic blood pressure of ≤ 130 mmHg and diastolic of ≤ 85 mmHg in subjects 18 and older and for children (ages 13-17) blood pressure will be in the normal range based on standard tables which takes in to account gender, height and age.~* The mean 24 blood pressure must meet the same criteria as the office blood pressures outlined above.~* Subject must have normoalbuminuria (UAE \< 30 mg/24 hrs)~* If subject is a female she must not be breast-feeding, and not of child-bearing potential, defined as post-menopausal for at least 1 year or surgically sterile; if she is of child bearing potential, then she must be practicing one of the following methods of birth control: 1) condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), 2) contraceptives (oral or parenteral) initiated three months prior to study drug administration, 3) maintain a monogamous relationship with a vasectomized partner, or 4) total abstinence from sexual intercourse.~Exclusion Criteria:~* Type 2 diabetics and other types of diabetics such as those with maturity onset diabetes or the young (MODY) will be excluded on the basis of established clinical criteria.~* Subjects who have a history of hypertension or is taking any hypertensive medications.~* Females who are pregnant or express a desire to become pregnant during the study. Females who are breast-feeding. Refer to details in inclusion criteria above regarding females.~* Subjects who have a history of taking ACE inhibitors within the last six months or have a current indication for ACE inhibitor therapy.~* Subjects (18 years of age and over) with a current blood pressure above 130mmHg/85mmHg. Subjects (13-17 years of age) who do not meet the normal range based on the standard tables~* Subjects who are currently microalbuminuric i.e. 24hr albumin \> 30mg~* Subjects who have participated in an interventional clinical trial involving ABPM 6 months prior to this study.~* Subjects that have a diagnosis of chronic atrial fibrillation.~* Subjects with a lifestyle that would disrupt normal circadian rhythm (i.e. night-shift workers).~* Subjects with a current serious co-morbid condition for which life expectancy is \<2 years.~* Subjects with a history of non-compliance, or psychiatric disturbance that would preclude successful completion of the study.~* Inability to give informed consent.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Dippers - Placebo Treated (Type: PLACEBO_COMPARATOR): Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
- NonDippers - Placebo Treated (Type: PLACEBO_COMPARATOR): Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
- NonDippers - Ramipril Treated (Type: ACTIVE_COMPARATOR): Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).

Based on this trial design, predict the completion outcome and termination type (if applicable).